Real-World Experience with Dolutegravir-Based Two-Drug Regimens.
Douglas WardMoti RamgopalDavid J RiedelCindy GarrisShelly DhirJohn WallerJenna RobertsKatie MycockAlan OglesbyBonnie CollinsMegan DominguezJames PikeJoseph MrusPublished in: AIDS research and treatment (2020)
Prior to commercial availability of the single-tablet 2DRs, DTG 2DR components were primarily used in treatment-experienced patients for treatment simplification and avoidance of long-term toxicities. Many of these patients achieved and maintained virologic suppression, with low discontinuation rates.